Mabwell's anti-ST2 monoclonal antibody 9MW1911 demonstrated dose-dependent reductions in COPD exacerbations in a Phase Ib/IIa trial, with the highest dose (900 mg) eliminating severe exacerbations entirely versus placebo. The compound shows a favorable safety profile and advances to Phase III testing, representing a new immunological approach to a disease characterized by persistent airway inflammation and recurrent acute episodes.
Key Points
- 900 mg dose eliminated severe COPD exacerbations versus placebo
- 81% reduction in moderate-to-severe exacerbations at highest dose
- Dose-proportional exposure with steady state by week 12
Longevity Analysis
COPD represents one of the most common causes of morbidity and premature mortality worldwide, with exacerbations driving accelerated lung function decline and systemic inflammation. An immunomodulatory approach targeting ST2 addresses a root mechanism of disease progression rather than symptomatic management alone. If Phase III results sustain these findings, this mechanism could alter the trajectory of respiratory decline in middle and older age, reducing the frequency and severity of the inflammatory cascades that extend beyond the lungs into circulation, energy metabolism, and regenerative capacity.
Original published by LT Wire.